Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal - PubMed (original) (raw)

Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal

David M Kent et al. Trials. 2010.

Abstract

Mounting evidence suggests that there is frequently considerable variation in the risk of the outcome of interest in clinical trial populations. These differences in risk will often cause clinically important heterogeneity in treatment effects (HTE) across the trial population, such that the balance between treatment risks and benefits may differ substantially between large identifiable patient subgroups; the "average" benefit observed in the summary result may even be non-representative of the treatment effect for a typical patient in the trial. Conventional subgroup analyses, which examine whether specific patient characteristics modify the effects of treatment, are usually unable to detect even large variations in treatment benefit (and harm) across risk groups because they do not account for the fact that patients have multiple characteristics simultaneously that affect the likelihood of treatment benefit. Based upon recent evidence on optimal statistical approaches to assessing HTE, we propose a framework that prioritizes the analysis and reporting of multivariate risk-based HTE and suggests that other subgroup analyses should be explicitly labeled either as primary subgroup analyses (well-motivated by prior evidence and intended to produce clinically actionable results) or secondary (exploratory) subgroup analyses (performed to inform future research). A standardized and transparent approach to HTE assessment and reporting could substantially improve clinical trial utility and interpretability.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Black D. The limitations of evidence. J R Coll Physicians Lond. 1998;32:23–26. - PMC - PubMed
    1. Feinstein AR, Horwitz RI. Problems in the "evidence" of "evidence-based medicine". Am J Med. 1997;103:529–535. doi: 10.1016/S0002-9343(97)00244-1. - DOI - PubMed
    1. Caplan LR. Evidence based medicine: concerns of a clinical neurologist. J Neurol Neurosurg Psychiatry. 2001;71:569–574. doi: 10.1136/jnnp.71.5.569. - DOI - PMC - PubMed
    1. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet. 1995;345:1616–1619. doi: 10.1016/S0140-6736(95)90120-5. - DOI - PubMed
    1. Rothwell PM, Mehta Z, Howard SC, Gutnikov SA, Warlow CP. Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet. 2005;365:256–265. - PubMed

Publication types

MeSH terms

LinkOut - more resources